Department of Pharmacy, Centro di Riferimento Oncologico (CRO) di Aviano-IRCCS, National Cancer Institute, Aviano, Italy.
Adv Ther. 2018 Oct;35(10):1497-1509. doi: 10.1007/s12325-018-0791-0. Epub 2018 Sep 14.
Colorectal cancer is the second most common cancer, representing 13% of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of action and the most common adverse reaction is skin toxicity. The main purpose of this manuscript is to present an update on the evidence-based summary of efficacy and safety and on the cost-effectiveness of cetuximab. Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug.
结直肠癌是第二大常见癌症，占所有诊断癌症的 13%。西妥昔单抗是一种重组嵌合单克隆 IgG1 抗体和表皮生长因子受体（EGFR）抑制剂。西妥昔单抗被批准与化疗联合用于一线治疗，或在 EGFR 表达、RAS 野生型转移性结直肠癌患者中对化疗失败或不耐受的患者中作为单一药物使用。西妥昔单抗的疗效来自于批准该药物的研究。西妥昔单抗耐受性良好；其毒性与其作用机制有关，最常见的不良反应是皮肤毒性。本文的主要目的是提供关于西妥昔单抗疗效和安全性的基于证据的总结以及成本效益的最新信息，并提出管理药物不良反应的建议，以提高药物的耐受性。
